REPLIMUNE GROUP, INC. Debt Securities Available For Sale Excluding Accrued Interest
REPLIMUNE GROUP, INC. (REPL) had Debt Securities Available For Sale Excluding Accrued Interest of $9.97 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Assets
us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest · last filed 2026-08-14
- 2026-06-30: Debt Securities Available For Sale Excluding Accrued Interest $9.97M.
- 2026-03-31: Debt Securities Available For Sale Excluding Accrued Interest $59.87M.
- 2025-12-31: Debt Securities Available For Sale Excluding Accrued Interest $146.19M.
- 2025-09-30: Debt Securities Available For Sale Excluding Accrued Interest $221.35M.
| Period end | Debt Securities Available For Sale Excluding Accrued Interest |
|---|---|
| 2026-06-30 | $9.97M 10-Q · filed 2026-08-14 |
| 2026-03-31 | $59.87M 10-Q · filed 2026-08-14 |
| 2025-12-31 | $146.19M 10-Q · filed 2026-02-03 |
| 2025-09-30 | $221.35M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $305.97M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $372.69M 10-K · filed 2026-06-29 |
| 2024-03-31 | $346.21M 10-K · filed 2024-05-16 |
| 2023-03-31 | $436.80M 10-K · filed 2024-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B |